Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The NASH Pipeline: Replete With Targets And New Compounds

Executive Summary

The numerous different targets of investigational drugs for the treatment of NASH suggest the jury is still out on which mechanism of action is most likely to prove effective against the condition. Ireland’s Afimmune is the latest company wanting to advance an investigational drug for the disorder into late-stage clinical studies.


Related Content

Finance Watch: Summer Slowdown Begins Ahead Of BIO, But Two IPOs Launched
Genfit's Enrollment Delay In NASH May Aid Intercept's First-To-Market Goal
Cirius Suspects Insulin Resistance Is Underlying Key To NASH
Intercept Hopes Statin Trial Will Lessen Ocaliva's Perceived CV Risk
Madrigal Believes It Holds The Key To NASH: Clearing The Fat
Viking Flexes Its Muscles Ahead Of Partnering Talks
Gilead, With Two PRVs In Hand, Holds Options For Accelerating Late-Stage Pipeline
Full Data For Intercept's Liver Disease Drug Show Rivals Where To Differentiate
Fatty Liver Diseases: A Public Health Concern, But Market Opportunity
Ocaliva OK'd; Will NASH Success, Acquisition Be Next For Intercept?


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts